Detalhe da pesquisa
1.
Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19.
N Engl J Med
; 385(13): 1184-1195, 2021 09 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-34347950
2.
TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial.
Gastroenterology
; 161(5): 1475-1486, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34310978
3.
Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial.
Hepatology
; 74(4): 1809-1824, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33811367
4.
Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial.
JAMA
; 327(5): 432-441, 2022 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35029629
5.
Subcutaneous REGEN-COV Antibody Combination in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial.
medRxiv
; 2021 Sep 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-34159343
6.
Subcutaneous REGEN-COV Antibody Combination for Covid-19 Prevention.
medRxiv
; 2021 Jun 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-34159344